Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 3,960 Shares of Stock

Natera, Inc. (NASDAQ:NTRAGet Free Report) CEO Steven Leonard Chapman sold 3,960 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $118.21, for a total value of $468,111.60. Following the completion of the transaction, the chief executive officer now directly owns 189,762 shares of the company’s stock, valued at approximately $22,431,766.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

  • On Monday, October 21st, Steven Leonard Chapman sold 1,709 shares of Natera stock. The shares were sold at an average price of $120.76, for a total transaction of $206,378.84.
  • On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20.
  • On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52.
  • On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total transaction of $663,874.53.

Natera Price Performance

Shares of NASDAQ NTRA traded up $1.99 during midday trading on Wednesday, reaching $126.73. 794,882 shares of the stock traded hands, compared to its average volume of 1,316,621. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The stock has a market capitalization of $15.67 billion, a PE ratio of -51.71 and a beta of 1.53. Natera, Inc. has a one year low of $37.67 and a one year high of $133.54. The company’s 50 day moving average is $123.31 and its 200 day moving average is $111.82.

Natera (NASDAQ:NTRAGet Free Report) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.97) EPS. On average, equities research analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current year.

Institutional Trading of Natera

Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Itau Unibanco Holding S.A. purchased a new stake in Natera during the 2nd quarter valued at $28,000. Quarry LP increased its stake in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC increased its stake in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the period. Tobam purchased a new stake in Natera in the second quarter worth $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Natera in the first quarter worth $83,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. BTIG Research upped their price target on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Robert W. Baird increased their target price on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. TD Cowen increased their target price on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. UBS Group reduced their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $150.00 target price on shares of Natera in a report on Friday, September 13th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $125.69.

Get Our Latest Research Report on NTRA

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further Reading

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.